Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

← catalyst calendar

NCT04365868 · results posted

Sponsored by Galectin Therapeutics Inc. (industry) · GALT — their whole pipeline →.

Phase
Phase 2/3
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
357actual
Sites
156
Countries
Argentina, Australia, Belgium +12

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2020-06-25actualWhen the study began enrolling
Primary completion2025-03-11actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-04-10actualThe whole study's end, after follow-up
First posted2020-04-28actualWhen this record first appeared on the registry
Results posted2026-06-30actualWhen the sponsor posted results to the registry
Record updated2026-06-30actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Prevention of Esophageal Varices
  • NASH - Nonalcoholic Steatohepatitis
  • Cirrhosis

Interventions

  • Drug: belapectin — also filed as GR-MD-02, galactoarabino rhamnogalacturonate
  • Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF
Proportion of Patients in the Belapectin Treatment Groups Who Develop New Esophageal Varices at 78 Weeks [18 Months] of Treatment Compared to Placebo
measured At 78 weeks [18 months]

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-08-09 · 14.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-11-13 · 2.5 MB · SAP_001.pdf

Permalink · GALT's whole pipeline · Catalyst calendar · Every registered study · What changed